



VIA HAND DELIVERY FEBRUARY 10TH, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: YOUNG et al.

Application Serial No.: 10/046,433

Art Unit: 1646

Filed: January 16, 2002

Examiner: O'Hara, E.

For: Human Tumor Necrosis Factor
Receptors TR13 and TR14.

Attorney Docket No.: PF511P1

7/a
P.G.J
2/24/03

Election And Response With Traverse Under 37 C.F.R. § 1.143

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed January 10, 2003 (Paper No. 5), please consider the following amendments, provisional election, traversal, and remarks. Applicants respectfully request that the Examiner enter the following amendments prior to examination of this application.

Applicants submit concurrently herewith: (a) a Fee Transmittal Sheet, accompanied by the appropriate fees; (b) a Version With Markings Showing Changes Made; and (c) an Information Disclosure Statement accompanied by form PTO/SB/08.

In the Claims:

~~Please cancel claims 2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 22, 24-27, 31, 32, 39, 41 to 43, 45, and 47 to 63 without prejudice or disclaimer.~~

Please replace claims 1, 7 and 33 with the following amended claim:

a1
-1. (Once Amended) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

02/12/2003 SMINASS1 00000011 083425 10046433

01 FC:1202 486.00 CH